KRAS G12A
Clinical trials for KRAS G12A explained in plain language.
Never miss a new study
Get alerted when new KRAS G12A trials appear
Sign up with your email to follow new studies for KRAS G12A, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New pill takes on hard-to-treat KRAS cancers in first human trial
Disease control Recruiting nowThis early-phase study tests a new drug called BBO-11818 in adults with advanced lung, pancreatic, or colorectal cancers that have a KRAS mutation. The main goals are to check safety and find the best dose, while also seeing if the drug can shrink tumors. About 387 participants w…
Matched conditions: KRAS G12A
Phase: PHASE1 • Sponsor: TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) • Aim: Disease control
Last updated May 01, 2026 15:59 UTC
-
New pill targets hard-to-treat cancers with KRAS and BRAF mutations
Disease control Recruiting nowThis study tests an experimental oral drug, S241656, in adults with advanced cancers that have certain gene changes (like KRAS or BRAF mutations). The drug is given alone or with other cancer treatments. The goal is to find safe doses and see if the drug can shrink tumors. About …
Matched conditions: KRAS G12A
Phase: PHASE1, PHASE2 • Sponsor: Institut de Recherches Internationales Servier • Aim: Disease control
Last updated May 01, 2026 15:58 UTC